Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know
CRISPR Therapeutics AG (CRSP) closed at $47.69 in the latest trading session, marking a -4.79% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 1.36%. Elsewhere ...
A Dallas-based biotech company called Colossal Biosciences says it has produced “de-extinct” dire wolf pups using ...
After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...
PerturbAI, an AI-native therapeutics company accelerating drug discovery through systems-level understanding of diseases, emerged from stealth today with the public release of the world's largest in ...
The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a ...
Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical ...
One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...
Researchers are applying CRISPR-Cas9 as a stoichiometric binding tool to improve NGS library normalization. The ...
Cathie Wood’s ARK Invest added to several beaten-down technology and biotech names while trimming positions elsewhere. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results